ChinaMAP unlocks its biobank

Medical researchers on the China Metabolic Analytics Project work in a lab. ChinaMAP, spearheaded by the Ruijin Hospital-based National Clinical Research Center for Metabolic Diseases in collaboration with a number of research institutions and hospitals nationwide, is a comprehensive cohort study project spanning the country. These include 150,000 participants from a national diabetes survey, 200,000 from a national cardiovascular metabolism and malignant tumor cohort study, 2.5 million from the National Metabolic Management Center, 3,600 from a national adolescent severe obesity cohort study, and 12,000 from a blood pressure target study for adults with type 2 diabetes. For instance, the national cardiovascular metabolism and malignant tumor cohort study initiated by the Ruijin Hospital's endocrinology team was a multi-center prospective longitudinal follow-up study in natural population. Given the potential in drug target research derived from the biobank, Ruijin Hospital's endocrinology team said it is actively preparing for transforming drug development outcomes in collaboration with multiple renowned global pharmaceutical companies.